Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy

close

Get every new post delivered right to your inbox.

Original Source